In conclusion, treatment with once-weekly subcutaneous semaglutide in conjunction with behavioral intervention in adults with overweight (with at least one weight-related comorbidity) or obesity (without diabetes) was associated with clinically impactful and sustained weight loss of 15.2% at week 104, along with improvements in weight-related cardiometabolic risk factors
Among those who stayed on treatment for the full 68 weeks, cagrilintide 2.4 mg delivered an average of about 12% body weight reduction , compared to 2.3% for placebo
What Happens When You Stop Taking Semaglutide Stopping semaglutide is rarely abrupt due to its long half-life
We provide access to a team that can help you tweak your diet if you hit a plateau or struggle with side effects
Rhiner, C., Gysi, S., Frohli, E., Hengartner, M
AgelessRx works in the telehealth-plus-pharmacy lane, meaning a licensed provider evaluates you virtually and then routes a written prescription down one of those two paths